Communiqués LianBio

Actions

LIANY

US53000N1081

Temps Différé OTC Markets Autres places de cotation 20:03:03 16/07/2024			Varia. 5j.	Varia. 1 janv.
0,3 ^USD	+0,60 %		0,00 %	-93,29 %

10/05	La société chinoise Zeekr fixe le prix de son introduction en bourse aux États-Unis au niveau le plus élevé de la fourchette indiquée pour lever 441 millions de dollars	RE
07/05	Zeekr, la filiale de Geely spécialisée dans les véhicules électriques, vise jusqu'à 367,5 millions de dollars lors de son introduction à la Bourse de New York	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

LianBio Announces Voluntarily Delisting from Nasdaq	28/02	AQ
LianBio Announces Completion of Strategic Review	13/02	AQ
LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets	26/12	AQ
LianBio Announces Departure of Chief Financial Officer	20/12	AQ
LianBio Announces Departure of Chief Executive Officer	19/12	AQ
LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences	06/12	AQ
LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences	01/12	AQ
LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update	13/11	AQ
LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis	30/10/23	AQ
LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023	25/10/23	AQ
LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets	24/10/23	AQ
LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology	28/08/23	AQ
LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update	14/08/23	AQ
LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations	03/08/23	AQ
LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis	26/07/23	AQ
LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and Thailand	18/07/23	AQ
LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023	17/07/23	AQ
LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations	12/07/23	AQ
LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore	26/06/23	AQ
LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis	08/06/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués LianBio

Actions

LIANY

US53000N1081

Communiqués

Filtres